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Insect venom allergy (IVA) may result in the most severe systemic reactions seen in allergology. The only potentially
curative treatment option is venom immunotherapy (VIT) over 3 to 5 years. This treatment is effective in more than
90% of subjects but no reliable predictors of VIT effectiveness exist. Sting challenge with a living insect can be
performed to assess the effectiveness of VIT: the predictive value of sting challenge can be highly sensitive in
patients with honeybee venom allergy whereas in yellow jacket allergy, a negative result can be reliable if the
challenge has been repeated at least 3 times.
The analysis of gene expression may be a step towards personalized venom immunotherapy assessing the
effectiveness of treatment, the minimal required time for VIT and the persistence of long term tolerance induced by
the treatment. Recent studies have enabled construction of a predictive model that could potentially be used in
clinical practice to assess the efficacy of insect venom immunotherapy. A set of 69 genes that may be responsible
for long-term protection was identified. Further analysis of the previously identified 6 transcripts make up the 18
gene predictive peripheral blood showed differences in patients treated with IVA. Further studies are needed to
investigate the usefulness of gene expression analysis and other markers in the prediction of VIT effectiveness.
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Genetic analysis has now become routine in several fields
of medicine (e.g. oncology, haematology). The first ex-
ample of the pharmacogenetic approach is the Mamma-
Print test analyzing the expression of 70 genes from an
early-stage breast cancer tissue sample to figure out if the
cancer has a low or high risk of recurrence within 10 years
of diagnosis. As a result, the patients are grouped into 2
categories of recurrence risk: low, (less than 10% without
additional treatment) and high (more than 29% without
additional treatment). The test can prevent the develop-
ment of side effects of chemotherapy in patients with a low
risk of recurrence [1]. The analysis of KIT mutations in the
diagnosis of systemic mastocytosis [2] and the PDGFRA/
FIP1L1 fusion gene in hypereosinophilic syndrome [3] are
rare examples of the application of pharmacogenetics in* Correspondence: mnied@gumed.edu.pl
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distribution, and reproduction in any mediumallergology. The current data do not support the wide-
spread, everyday, clinical use of DNA or RNA analysis in
other allergic diseases [4]. Research on gene expression in
allergen immunotherapy is less developed by comparison
with studies on asthma and oncology. The number of pub-
lications on gene expression and allergen immunotherapy
gathered in PubMed database in July 2013 was only 126
(among them 20 on insect venom allergy). By comparison,
gene expression was described in 3,302 publications on
asthma and 15,734 on lung cancer. However it seems that
it is only a matter of time before this situation changes.
The analysis of DNA describes the “anatomy” of our gen-
ome as polymorphisms and mutations, which may be re-
sponsible for differences in the phenotype. The anatomy of
the gene is stable and depends on heredity. Somatic muta-
tions are the exception, as they can occur at any moment
of life. In general when we analyze the genome by PCR
(polymerase chain reaction) or GWAS (genome-wide asso-
ciation study) the majority of the information (except som-
atic mutations) will be valid throughout the individual’sntral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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vary in the course of the disease and furthermore, can be
modified by treatment. Thus single gene expression ana-
lysis and whole genome expression studies describe the
function of the genome at the time of the analysis. Both
studies on DNA and RNA may help to tailor the personal-
ized treatment of the patient.
The data obtained from studies on whole genome ex-
pression or GWAS are large and difficult to analyze with-
out the mathematical tools to support the diagnosis.
Furthermore the large datasets of electronic medical re-
cords can be combined with the genetic data and help to
establish the clinical decision [4].
The unanswered questions in insect venom allergy
The only treatment addressing the cause of IVA is venom
immunotherapy (VIT) for 3 to 5 years. In more than 95%
of subjects the treatment is effective, as demonstrated by
sting challenges or field stings. None of the in vitro
methods used so far may replace the sting challenge and
predict ineffectiveness of VIT. The data published in the
Cochrane Review of insect venom immunotherapy did not
identify any difference in the effectiveness of VIT in the
compared patient groups or modes of immunotherapy [5].
The further part of the paper describes the components of
the decision support tool, which could be used in the fu-
ture to assess the effectiveness of VIT including clinical
data, coexistence of mastocytosis, gene expression results,
Tryptase levels and other in vitro markers.
Gene expression
Recently data on gene expression has been analyzed for
immunotherapy to grass, house dust mites and ovalbumin
[6-9]. Our research group has focused on the patients with
insect venom allergy [10-12]. Our aim was to define theFigure 1 Development of the prediction model assessing the efficacygene expression pattern to assess the effect of the treat-
ment with a less invasive method than the sting challenge
and to assess the risk of the development of mastocytosis,
which can predict the lack of long-term protection of VIT.
There is still an unanswered question in allergology relat-
ing to the long-term protection achieved by immunother-
apy [10,11]. Retrospective analysis in relation to field
insect sting reactions can be an easy marker of the toler-
ance gained by the treatment. Our study on the prediction
of the effectiveness of venom immunotherapy was per-
formed in few patient groups: patients before venom im-
munotherapy, on the maintenance phase of the treatment,
those treated with the VIT in the past who were stung and
tolerated the venom, and those who did not benefit from
VIT. The results of the study indicate that the effective-
ness of VIT can be assessed with gene expression studies
[10]. Differences in gene expression are related to the
known mechanisms in differentiation of T lymphocytes,
mast cell activation genes related to FcγR1, JAKSTAT,
MAPK, Wnt, and calcium channels pathways. It also recog-
nizes new genes such as TWIST-2, CLDN1 and PRLR as
predictors of VIT effectiveness. TWIST-2 is a transcription
factor stimulating IL-10 and decreasing IL-4 expression.
CLDN 1 is an adhesion molecule, which enables the migra-
tion of dendritic cells and is related to the TGF-β level.
However the transcripts of established function are only
a proportion of the genes that show clinical relevance in
differentiating between effectively and non – effectively
treated patients. Most of the genes have an unknown func-
tion and the functional studies on their activity opens new
field of research and let us realize how far we are from un-
derstanding the mechanisms of immunotherapy [10,11].
The gene expression profile indicated by the results of the
study enables the construction of a prediction model, which
could be used in clinical practice to assess the efficacy ofof VIT.
Figure 2 Use of the prediction model in the group of patients during the maintenance phase of VIT.
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achieved venom tolerance were compared with subjects who
did not tolerate the insect sting. The genes in the model were
selected out of 48,804 probes on the array by the fold change
in expression above 3, t-test p < 0.0015, Benjamin Hochberg
correction for multiple testing p < 0.005. The set of 18 genes
gave prediction results similar to the sets composed of a
higher number of genes (Figure 1) [10].
For the second stage, the gene model was tested on
patients who were treated with venom immunotherapy
predicting the effectiveness of VIT in 88% of treated sub-
jects (Figure 2) [10]. Further analysis compared patients
(groups 1 versus 2) before immunotherapy with the group
on the maintenance phase of immunotherapy and patients
before immunotherapy with those who were treated in theFigure 3 Differences in expression of the genes in the course of imm
the maintenance phase, 3 – patients who were treated in the past anpast and showed field sting tolerance (group 3) (Figure 3).
As a result, a set of 89 genes that may be responsible for
long term protection was identified. These genes are
common in both comparisons, being differently expressed
during the maintenance phase of VIT but still maintaining
this pattern years after the end of VIT when long term
tolerance is still protecting the patients. Furthermore
when we analyzed these genes, we found among them six
transcripts (C16ORF13, HS.583392, HS.532515, PRLR,
TWIST2) [10], which compose the 18 genes prediction
model of the effectiveness of VIT [11].
Other components of the prediction model
The data published in the Cochrane Review, mentioned
above, did not indicate any clinical marker that couldunotherapy (patient group 1 – before immunotherapy, 2 – during
d achieved long term tolerance).
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spective data performed in patients treated with immuno-
therapy who also suffered from mastocytosis has shown
impairment of effectiveness in comparison to the general
population of treated subjects. However the risk benefit ra-
tio favours VIT as untreated patients with mastocytosis with
IVA are at risk of a fatal reaction [13]. The severity of the
reaction to an insect sting is linearly correlated with the
tryptase level [14]. The analysis of whole gene expression
showed a difference in expression of both the mastocytosis
patient who experiences an anaphylactic reaction to an in-
sect sting in their medical history and the pattern of expres-
sion that can differentiate between a patient with
mastocytosis and the general population [11,15].
Gene expression studies have also been performed in
subjects with other allergic diseases. Gene expression
was studied in a murine model of oral desensitization to
ovalbumin, which showed differences in the intestinal
epithelial cells [8]. A difference in gene expression was
found in nasal mucosa as a result of pollen immuno-
therapy [7,16]. The improvement of molecular diagnos-
tic methods in allergology has become one of the major
scientific aims of the European Academy of Allergology
and Clinical Immunology [17].
In summary, we can hypothesize the future develop-
ment of a clinical tool, which can be used to address the
currently unanswered question relating to the efficacy of
insect venom immunotherapy, being created from clin-
ical data, tryptase levels and gene expression studies div-
iding patients into 2 groups: those treated effectively and
those not achieving clinical protection who require more
intensive treatment.
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